carbamazepine reference
Reference image
(carbamazepine · DailyMed)
PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.) Zimbabwe · MCAZ

NONE

CARBAMAZEPINE

2026/13.1/7329 TABLET; ORAL 400mg nervous system INN generic

What it does

Carbamazepine is a medication used to treat seizures and certain types of nerve pain. It belongs to a class of drugs called antiepileptics.

Commonly used for: seizures (epilepsy), nerve pain (neuropathic pain)

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
2026/13.1/7329
Registration date
2026-03-03
Expiry date
2031-03-02
Status
PRESCRIPTION PREPARATIONS 9TH SCHEDULE, (P.P.)
Active ingredient
CARBAMAZEPINE
Dosage form
TABLET; ORAL
Strength
400mg
Pack size
-
Therapeutic class
-
ATC class (WHO)
N03AF - Carboxamide derivatives
Drug group
NERVOUS SYSTEM
RxNorm RxCUI
2002
Manufacturer / MAH
Medreich
Applicant / LTR
IMPERIAL MEDICAL SOLUTIONS
Country of origin
-
Manufacturer location
No 4/3, Avalahalli, Anjanpura Post, VHG9+92M, Off, Kanakapura Rd, Bank Colony, Konanakunte, Bengaluru, Kothnur, Karnataka 560108, India

Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:09 · updated 2026-09-13 04:30:08

Drug Interactions

113
Check interactions

Pharmacodynamic Warnings

Carbamazepine appears in TABLE 1: Drugs that cause hepatotoxicity

Carbamazepine appears in TABLE 18: Drugs that cause hyponatraemia

Severe (15)

Antiepileptics - decreases absorption

Iron chelators (dexrazoxane) might decrease the absorption of antiepileptics (fosphenytoin, phenytoin). Avoid.

Severe Theoretical

Antiepileptics - decreases exposure

Lumacaftor is predicted to decrease the exposure to antiepileptics (carbamazepine, fosphenytoin, phenobarbital, phenytoin, primidone). Avoid.

Severe Theoretical

Antiepileptics - decreases concentration

St John’s wort is predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). Avoid.

Severe Theoretical

Antiepileptics - increases risk of overheating and dehydration

Hydroxyzine potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children.

Severe Theoretical

Antiepileptics - increases risk of overheating and dehydration

Haloperidol potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children.

Severe Theoretical

Moderate (47)

Antiepileptics - increases concentration

Intravenous chloramphenicol increases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) affect the concentration of intravenous chloramphenicol

Moderate Study

Antiepileptics - decreases concentration

Diazoxide decreases the concentration of antiepileptics (fosphenytoin, phenytoin) and antiepileptics (fosphenytoin, phenytoin) are predicted to decrease the effects of diazoxide. Monitor concentration

Moderate Anecdotal

Antiepileptics - increases concentration

Disulfiramincreasestheconcentrationofantiepileptics (fosphenytoin,phenytoin).Monitorconcentrationandadjust dose.rStudy →AlsoseeTABLE12p.1520

Moderate Study

Antiepileptics - increases concentration

Fluorouracilincreasestheconcentrationofantiepileptics (fosphenytoin,phenytoin).Monitorconcentrationandadjust dose.rAnecdotal 1xidneppA|snoitcaretnI A1 https://www.facebook.c (Books-Courses-Medic

Moderate Anecdotal

Antiepileptics - decreases concentration

Folates are predicted to decrease the concentration of antiepileptics (fosphenytoin, phenobarbital, phenytoin, primidone). Monitor concentration and adjust dose.

Moderate Study

Unknown (51)

Afatinib - decreases exposure

Carbamazepine is predicted to decrease the exposure to afatinib.

Unknown Study

Aliskiren - decreases exposure

Carbamazepine decreases the exposure to aliskiren.

Unknown Study

Antiepileptics - increases risk of overheating and dehydration

Acetazolamide potentially increases the risk of overheating and dehydration when given with antiepileptics (zonisamide). Avoid in children.

Unknown Theoretical

Antiepileptics - increases risk of visual disturbances

Alcohol potentially increases the risk of visual disturbances when given with antiepileptics (retigabine).

Unknown Study

Antiepileptics - decreases exposure

Enzalutamide is predicted to slightly decrease the exposure to antiepileptics (brivaracetam).

Unknown Theoretical

Data from BNF 85 (British National Formulary). This is not a substitute for professional medical advice. Matched via: class

Disclaimer: This information is sourced from Medicines Control Authority of Zimbabwe (Zimbabwe). Always consult a qualified healthcare professional before using any medication.

About this medicine

Carbamazepine is a medication used to treat seizures and certain types of nerve pain. It belongs to a class of drugs called antiepileptics.

What it treats

  • seizures (epilepsy)
  • nerve pain (neuropathic pain)

How it works

Carbamazepine helps stabilize electrical activity in the brain, reducing the frequency and severity of seizures.

Who it's for

This medication is for individuals with epilepsy or specific nerve pain conditions.

Drug class

Antiepileptics

Cautions

  • • Be careful if you are taking drugs that can harm the liver.
  • • Be cautious if you are taking medications that can lower sodium levels in the blood.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: Carbamazepine

BNF-referenced

Carbamazepine is an antiepileptic drug primarily used to manage epilepsy, particularly focal and generalized tonic-clonic seizures. It is also indicated for other conditions such as trigeminal neuralgia and bipolar disorder. Carbamazepine functions by inhibiting sodium channels, thereby reducing neuronal excitability and stabilizing mood in bipolar disorder. It has a narrow therapeutic index, necessitating careful monitoring of plasma levels to avoid toxicity.

Indications

  • Epilepsy (focal and generalized tonic-clonic seizures)
  • Trigeminal neuralgia
  • Bipolar disorder (manic episodes)
  • Adjunctive therapy in acute alcohol withdrawal
  • Diabetic neuropathy

Dosage

Children: For children

Adults: Initially, 100 mg 1-2 times a day, increased gradually according to response; usual dose 200 mg 3-4 times a day, increased if necessary up to 1.6 g daily.

Mechanism of action

Carbamazepine's mechanism of action is associated with its ability to inhibit voltage-dependent sodium channels, which reduces the firing of action potentials and stabilizes neuronal membranes. This results in decreased polysynaptic nerve responses and inhibition of excessive neuronal firing, effectively controlling seizure activity. In bipolar disorder, it may enhance GABA transmission and increase dopamine turnover, alleviating manic and depressive symptoms.

Pharmacodynamics

Carbamazepine exhibits anticonvulsant effects by limiting high-frequency repetitive firing of action potentials in neurons. It shows effectiveness in treating manic episodes in bipolar disorder and alleviating pain associated with trigeminal neuralgia. The drug has a narrow therapeutic index, which requires careful dose management to balance efficacy with the risk of adverse effects. Genetic variations can affect carbamazepine metabolism and efficacy, with certain genotypes conferring resistance to treatment.

Pharmacokinetics

Carbamazepine is well absorbed orally and undergoes extensive hepatic metabolism, primarily by cytochrome P450 enzymes. It has a half-life of about 12-17 hours, but this can decrease with chronic use due to autoinduction of its metabolism. The drug is primarily excreted in urine as metabolites, with only a small fraction excreted unchanged. Plasma levels should be monitored, particularly in patients with significant genetic variations affecting drug metabolism.

Contra-indications

  • History of hypersensitivity to carbamazepine or any of its components
  • Bone marrow depression
  • History of aplastic anaemia or agranulocytosis associated with carbamazepine
  • Concomitant use with monoamine oxidase inhibitors

Adverse effects

  • Dizziness
  • Drowsiness
  • Nausea
  • Vomiting
  • Rash
  • Agranulocytosis
  • Aplastic anaemia
  • Hepatic dysfunction
  • Stevens-Johnson syndrome
  • Toxic epidermal necrolysis

Interactions

  • Carbamazepine + Antipsychotics (second-generation): Severe (increases risk of myelosuppression)
  • Carbamazepine + Clozapine: Severe (increases risk of myelosuppression)
  • Carbamazepine + Berotralstat: Severe (decreases concentration)
  • Carbamazepine + Ledipasvir: Severe (decreases exposure)
  • Carbamazepine + Lumacaftor: Severe (decreases exposure)
  • Carbamazepine + Sofosbuvir: Severe (decreases exposure)
  • Carbamazepine + Thrombin inhibitors: Severe (decreases exposure)
  • Carbamazepine + Dabigatran: Severe (decreases exposure)
  • Carbamazepine + Antifungals (azoles): Moderate (decreases efficacy)
  • Carbamazepine + Itraconazole: Moderate (decreases efficacy)

Precautions

  • Monitor hepatic function regularly, especially in long-term therapy
  • Caution in patients with a history of bone marrow suppression
  • Gradual withdrawal recommended to avoid seizure exacerbation
  • Consider genetic testing for HLA-B*1502 to assess risk of serious skin reactions in certain populations

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Monitor closely as carbamazepine may cause fetal harm.

Breast-feeding

Carbamazepine is excreted in breast milk. Caution is advised; monitor the infant for side effects.

Storage

Store

BNF 85 (British National Formulary) p.359 BNF for Children 2019-2020 p.222 PubChem / pathway

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: Carbamazepine

PubChem CID 2554

Molecular formula: C15H12N2O

Mechanism of action

Carbamazepine's mechanism of action is not fully elucidated and is widely debated. One major hypothesis is that carbamazepine inhibits sodium channel firing, treating seizure activity. Animal research studies have demonstrated that carbamazepine exerts its effects by lowering polysynaptic nerve response and inhibiting post-tetanic potentiation. In both cats and rats, carbamazepine was shown to decrease pain caused by infraorbital nerve stimulation. A decrease in the action potential in the nucleus ventralis of the thalamus in the brain and inhibition of the lingual mandibular reflex were observed in other studies after carbamazepine use. Carbamazepine causes the above effects by binding to voltage-dependent sodium channels and preventing action potentials, which normally lead to stimulatory effects on nerves. In bipolar disorder, carbamazepine is thought to increase dopamine turnover and increase GABA transmission, treating manic and depressive symptoms. A common issue that has arisen is resistance to this drug in up to 30% of epileptic patients, which may occur to altered metabolism in patients with variant genotypes. A potential therapeutic target to combat carbamazepine resistance has recently been identified as the EPHX1 gene promoter, potentially conferring resistance to carbamazepine through methylation. Anticonvulsant: Exact mechanism unknown; may act postsynaptically by limiting the ability of neurons to sustain high frequency repetitive firing of action potentials through enhancement of sodium channel inactivation; in addition to altering neuronal excitability, may act presynaptically to block the release of neurotransmitter by blocking presynaptic sodium channels and the firing of action potentials, which in turn decreases synaptic transmission. Antineuralgic: Exact mechanism unknown; may involve gamma-aminobutyric acid (GABAB) receptors, which may be linked to calcium channels. Antimanic; antipsychotic: Exact mechanism is unknown; may be related to either the anticonvulsant or the antineuralgic effects of carbamazepine, or to tis effects on neurotransmitter modulator systems. Antidiuretic: Exact mechanism unknown; may exert a hypothalamic effect on the osmoreceptors mediated via secretion of antidiuretic hormone (ADH), or may have a direct effect on the renal tubule. For more Mechanism of Action (Complete) data for CARBAMAZEPINE (8 total), please visit the HSDB record page.

Pharmacodynamics

**General effects** Carbamazepine treats seizures and the symptoms of trigeminal neuralgia by inhibiting sodium channels. In bipolar 1 disorder, carbamazepine has been found to decrease mania symptoms in a clinically significant manner according to the Young Mania Rating Scale (YMRS). Carbamazepine has a narrow therapeutic index. **A note on genetic variation and carbamazepine use** In studies of Han Chinese ancestry patients, a pronounced association between the HLA-B*1502 genotype and Steven Johnson syndrome and/or toxic epidermal necrolysis (SJS/TEN) resulting from carbamazepine use was observed.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.